A NSW town is classified high-risk for Japanese encephalitis. Residents did not know

Japanese encephalitis virus was detected for the first time in south-eastern Australia in 2022 [s1]. The public health response that followed did the things such responses are supposed to do: New South Wales mapped high-risk areas using detections of the virus in mosquitoes and animal hosts, human case data, and climate and environmental considerations, and defined which populations were eligible for vaccination, funded by Australian states and territories [s1].

Early evidence indicated slower-than-expected uptake in those high-risk areas [s1]. A qualitative study published in the Australian Journal of Rural Health in June went to one of them and asked why.

Where and how

The setting was Tamworth, classified as high-risk for Japanese encephalitis virus by NSW Health [s1]. The study was an interpretative qualitative design, conducting semi-structured interviews with 15 community participants, 7 general practitioners, 3 nurses and 3 pharmacists, analysed thematically using an inductive approach [s1].

That is a small sample by design — qualitative work of this kind is built to explain a mechanism, not to estimate a prevalence. It cannot tell you what proportion of Tamworth residents are vaccinated. It can tell you what the people who are not vaccinated say about why.

Theme one: risk awareness came from experience, not policy

The first theme the authors identify is risk awareness shaped by experience rather than policy [s1]. The participant quotation they report is direct: "I didn't realise Tamworth was identified as an area as well, I just was totally unaware" [s1].

The gap that describes is specific and worth naming precisely. NSW Health had done the surveillance, made the risk classification, and attached vaccine eligibility to it. What had not happened was the classification reaching the people it classified. A risk designation that exists in a health department's mapping but not in a resident's awareness produces no behaviour change at all.

Theme two: eligibility is not uptake

The second theme is that vaccine eligibility does not translate into uptake, illustrated by a participant observing "There isn't really much promotion at the moment" [s1].

This is a general principle that Japanese encephalitis in regional New South Wales happens to illustrate cleanly. Making a vaccine free and available removes cost and supply as barriers. It does not, on its own, create the demand — a person has to know the disease exists, believe they are at risk of it, know a vaccine exists, know they qualify, and act. Funding the vaccine addresses the last link in that chain and none of the earlier ones.

The parallel with other Pacific and Australasian vaccination programmes is close. Free provision without active recommendation has repeatedly produced coverage well below what eligibility implies.

Theme three: what the participants said would work

The third theme is building community-level preparedness through communication, captured in the call for "Messaging that the whole community knows about" [s1].

The authors' conclusion follows from that: despite early public health efforts, awareness of Japanese encephalitis and uptake of preventive measures remained limited in a high-risk regional setting, and supporting trusted healthcare providers with clear, consistent communication is critical to optimising vaccine uptake [s1].

The emphasis on providers is not incidental. The study interviewed GPs, nurses and pharmacists alongside community members [s1] — the design assumed that the channel matters, and the conclusion identifies that channel as the place to intervene.

What this study cannot say

It is one town, 28 interviews, and a qualitative design. It reports no vaccination coverage figures, no case counts, and no evaluation of any communication intervention. It cannot establish that better messaging would raise uptake — only that participants in a high-risk area described poor awareness and little promotion as the reasons they had not acted [s1].

It also says nothing about the individual risk any reader faces or about who should be vaccinated; eligibility in New South Wales is set by NSW Health based on the risk classification the study describes [s1], and this article is not guidance on it.

Why it matters beyond Tamworth

Japanese encephalitis virus arriving in south-eastern Australia in 2022 [s1] is the kind of event that vector-borne disease surveillance in Australia is increasingly expected to produce more of. The operational lesson here is about what happens after surveillance succeeds.

Australia's system detected a novel arboviral incursion, mapped it, funded a vaccine and defined an eligible population — genuinely fast public health work. The failure, on this evidence, occurred at the last step, in the distance between a risk map and a resident. That is a cheaper problem to fix than a surveillance gap, and a harder one to notice.

What to watch

Whether NSW Health's Japanese encephalitis communication approach changes in the next mosquito season, and whether vaccination coverage in designated high-risk local government areas is reported publicly. Neither is reported in this study.

Sources

• [s1] Community Perspectives on Japanese Encephalitis Risk and Prevention in an Endemic Region of Australia, Australian Journal of Rural Health, published online 23 June 2026. https://doi.org/10.1111/ajr.70227